TRVI trevitherapeutics.com: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

Trevi Therapeutics (TRVI) is developing innovative antitussive agents currently undergoing clinical trials. Tracking the company's EV/EBITDA valuation trend on GURU.Markets, we note that the value 0.00 describes the current enterprise value. The strategy is based on the launch of Haduvio for the treatment of pruritus; however, the risk of regulatory rejection and the need for capital create uncertainty for the biopharmaceutical startup's development.

The EV/EBITDA ratio compares the total value of assets and net debt to operating profit, allowing an investor to determine the degree of business undervaluation relative to market peers. When analyzing the historical EV/EBITDA ratio of the business, one should evaluate the capitalization potential of Trevi Therapeutics (TRVI) through future sales of Haduvio to patients with chronic cough and itch whose therapy is covered by medical insurers.